表皮生长因子受体-酪氨酸激酶抑制剂在非小细胞肺癌中的应用进展

Progress of EGFR-TKI in treatment of non-small cell lung cancer

肺癌发病率逐年攀升，化疗的疗效已达到一个平台期，随着分子生物学研究的深入，靶向治疗特别是表皮生长因子受体-酪氨酸激酶抑制剂为非小细胞肺癌的治疗开辟了蹊径。本文就表皮生长因子受体一酪氨酸激酶抑制剂在非小细胞肺癌中的应用作一综述。

Lung cancer has become one of the most common malignant tumors. Research of chemotherapy has come to its plateau. Molecular targeted therapy has become a new approach in the treatment of advanced non-small cell lung cancer. In this review, we discuss the research of epidermal growth factor receptor-tyrosine kinase inhibitor in the treatment of non-small cell lung cancer.